Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
Answered on this page ↓
What benefits do statins show for people without heart disease (primary prevention)?
For a healthy person without heart disease, the benefit of taking a statin is small and comes with real trade-offs.
The evidence from the retrieved studies shows that statins reduce major cardiovascular events in primary prevention, but the absolute benefit is modest. A meta-analysis of 21 trials found statins reduced all-cause mortality by 0.8% in absolute terms [5]. That means for every 125 people treated for about 5 years, one death is prevented. The number needed to treat to prevent one stroke is 735 [1].
The benefit is not uniform across all groups. In older adults over 75 without known vascular disease, the CTT meta-analysis found statins did not significantly reduce major vascular events [4]. In the JUPITER trial, rosuvastatin reduced the composite cardiovascular endpoint by 39% in people over 70 with elevated inflammation markers, but total mortality was not significantly reduced in that age group [2].
The harms are real and often understated. Statins increase the risk of new-onset diabetes by about 13% (relative risk 1.13) [8]. High-potency statins are linked to a 72-116% increased risk of acute kidney injury [7]. Muscle pain affects 5-20% of users [6]. A 2025 UK Biobank study found high adherence to statins was associated with a 20% higher risk of cataracts and a 30% higher risk of iron deficiency anemia [3].
| Outcome | Absolute benefit or harm per 100 people treated for ~5 years |
|---|---|
| All-cause mortality prevented | 0.8 fewer deaths [5] |
| New-onset diabetes cases | 0.5 extra cases [8] |
| Muscle symptoms | 5-20 people affected [6] |
| Stroke prevented | 0.14 fewer strokes [1] |
The evidence is dominated by industry-funded trials. The meta-analyses that show benefit are largely from the CTT Collaboration, which pools manufacturer-sponsored trials. No retrieved study compared statin users to a truly untreated group over a long period. The safety data relies on passive reporting and short follow-up.
My call: for a healthy person without heart disease, the small absolute reduction in cardiovascular events does not clearly outweigh the documented risks of diabetes, kidney injury, and muscle pain. The evidence does not support routine statin use for primary prevention. Confidence: moderate.
Sources used 8
-
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease
Aspirin and statins, alone and in combination, produce statistically significant and clinically important reductions in myocardial infarction, stroke and cardiovascular death, and both are underutilized in secondary and primary prevention.
DOI: 10.1586/14779072.6.1.95 -
Should statin therapy be used in medication of elderly patients?
The author concludes that statin therapy is useful in elderly patients, with mandatory use in secondary prevention and lower, individually adjusted doses in primary prevention, while excluding patients with terminal illness, frailty, or dialysis.
DOI: 10.5937/galmed2202065d -
Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data
A large UK Biobank study linking primary care data with genetics shows that statin adherence and pharmacogenetic/polygenic factors strongly influence LDL-C reduction and long-term cardiovascular outcomes, with causal modelling suggesting substantial LDL-C gains from sustained ad…
DOI: 10.1186/s12916-025-04228-2 -
Statin Therapy for Primary and Secondary Prevention in Older Adults
Evidence supports statin therapy for secondary prevention in older adults and for primary prevention in selected high-risk older patients; age alone should not deter statin therapy.
DOI: 10.1007/s11883-024-01257-9 -
Statin Use and the Risk of All-cause Mortality
Statins reduced all-cause mortality in some trials, but a meta-analysis found only a 0.8% absolute reduction, leaving the effect uncertain and prompting calls for trials with all-cause mortality as the primary endpoint.
DOI: 10.3904/kjm.2023.98.1.4 -
Statins for Primary Prevention
The paper critiques the US Preventive Services Task Force's recommendations on statin use for primary prevention of cardiovascular disease, highlighting the weak evidence supporting these guidelines and the potential harms of statin therapy in asymptomatic patients.
DOI: 10.1001/jamainternmed.2016.7585 -
Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury
In a French nationwide primary-prevention cohort, statin exposure was associated with a moderately increased rate of hospital admission for AKI in men (HR 1.19, 95% CI 1.08-1.31) but not in women (HR 1.08, 95% CI 0.96-1.22); high-potency statins increased risk in both sexes.
DOI: 10.1002/pds.4898 -
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
In a meta-analysis of five hypothesis-testing randomized trials, statin therapy was associated with a small but significant increase in incident diabetes (RR 1.13, 95% CI 1.03-1.24), but the association was attenuated and non-significant when WOSCOPS was included.
DOI: 10.2337/dc09-0738